Royal Bank of Canada is a leading financial services institution that provides a wide range of banking and financial solutions to individuals, businesses, and institutions. The bank offers personal and commercial banking services, wealth management, investment banking, and capital markets services. With a robust network of branch locations and digital platforms, it aims to meet the diverse needs of its clients while focusing on innovation and customer service. Royal Bank of Canada is committed to enhancing the financial well-being of its customers and leveraging its expertise to support economic growth in the communities it serves. Read More
Shares of residential solar energy company Sunrun (NASDAQ:RUN) jumped 10.2% in the afternoon session after the stock rebounded following several positive analyst actions and favorable sector-wide news. RBC Capital upgraded the stock to "Outperform" from "Sector Perform," and Wells Fargo raised its price target, with both citing increased clarity on long-term opportunities following recent U.S. Treasury guidance. GLJ Research also upgraded its rating on the company. This guidance appears to be a key factor, with analysts noting it's favorable for the residential solar sector. Adding to the positive sentiment for renewable energy, India announced it was more than halving its goods and services tax on related equipment, including solar panels, from 12% to 5%, shoring up the industry.
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS)
jumped 6.3% in the afternoon session after extending its positive momentum as RBC Capital Markets raised its price target on the company.
Shares of buy now, pay later company Affirm (NASDAQ:AFRM) jumped 5.6% in the afternoon session after several analysts raised their price targets on the stock following the company's recent strong financial results. Among the firms updating their outlook, Mizuho increased its price target to $108 from $70, while maintaining an Outperform rating. Similarly, UBS raised its target to $85 from $56, keeping a Neutral rating. RBC Capital adjusted its price target upward to $97 from $75, and Stephens lifted its target to $93 from a previous $69. These upward revisions signal growing confidence from Wall Street in the company's financial performance and future prospects.
Shares of life sciences company Avantor (NYSE:AVTR)
fell 2.7% in the afternoon session after RBC Capital Markets lowered its price target on the stock to $16 from $17.
RBC Capital upgraded Bio-Techne, citing M&A confidence, margin gains, and growth potential after a sharp stock drop and alignment with sector valuations.
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS)
jumped 1.5% in the afternoon session after RBC Capital Markets raised its price target on the company. The investment bank increased its forecast for the stock's price to $50 from a previous target of $46. This move suggests that the analyst sees a higher potential value for the company's shares. However, it is important for investors to note that RBC maintained its "Sector Perform" rating on Exact Sciences. This type of rating indicates that the firm expects the stock to perform in line with the broader healthcare diagnostics sector, rather than significantly outperforming it. The price target adjustment without a formal rating change often reflects updated financial modeling or a revised view on market conditions.
Shares of biopharmaceutical company Incyte Corporation (NASDAQ:INCY)
jumped 2.4% in the afternoon session after Barclays initiated coverage on the stock with an Overweight rating, helping the shares reach a new 52-week high. The investment bank noted a "compelling inflection point" for the biotechnology firm, highlighting multiple maturing assets that could drive future revenue growth. Further bolstering investor confidence, RBC Capital raised its price target on Incyte to $72, citing strong demand-driven growth from its products. The stock's climb to a 52-week high of $87.27 reflects significant positive momentum, building on a 22.5% year-to-date return. The move was also supported by broader strength in the biotechnology sector and a positive technical trend, with the stock trading above its key 50-day and 200-day moving averages.
Shares of alcohol company Brown-Forman (NYSE:BF.B)
fell 2.4% in the afternoon session after competitor Constellation Brands warned of macroeconomic headwinds affecting consumer demand.
Shares of beer, wine, and spirits company Constellation Brands (NYSE:STZ)
fell 7.4% in the morning session after the company lowered its financial outlook for fiscal year 2026, citing a challenging macroeconomic environment and weakening consumer demand. The owner of popular brands like Corona and Modelo now projects comparable earnings per share of $11.30 to $11.60, a significant reduction from the prior forecast of $12.60 to $12.90. The company also expects a 4% to 6% decline in organic net sales. Management attributed the revision to a sudden drop in beer sales, noting that purchasing declines among Hispanic consumers—a key demographic—were particularly pronounced. This trend, combined with lower volumes and the impact of tariffs, prompted the more cautious outlook.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at engineered components and systems stocks, starting with RBC Bearings (NYSE:RBC).
Shares of alcohol company Brown-Forman (NYSE:BF.B)
fell 4% in the afternoon session after RBC Capital expressed caution about the company's near-term outlook, citing pressure in the U.S. market and challenges with its distribution network.
Shares of beer, wine, and spirits company Constellation Brands (NYSE:STZ)
fell 3% in the afternoon session after a downgrade from Bank of America Securities, which lowered its rating on the stock to Underperform from Neutral and slashed its price target.
Shares of beer, wine, and spirits company Constellation Brands (NYSE:STZ)
fell 3.3% in the afternoon session after RBC Capital trimmed its price target on the stock to $230 from $233, though it maintained an Outperform rating.
